NYKODE THERAPEUTICS ASA (NYKD.OL) Stock Fundamental Analysis
Europe - OSL:NYKD - NO0010714785 - Common Stock
2.238 NOK
-0.17 (-6.91%)
Taking everything into account, NYKD scores 3 out of 10 in our fundamental rating. NYKD was compared to 74 industry peers in the Biotechnology industry. While NYKD seems to be doing ok healthwise, there are quite some concerns on its profitability. NYKD does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year NYKD has reported negative net income.
In the past year NYKD has reported a negative cash flow from operations.
In the past 5 years NYKD reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: NYKD reported negative operating cash flow in multiple years.
1.2 Ratios
NYKD has a Return On Assets of -17.27%. This is in the better half of the industry: NYKD outperforms 60.81% of its industry peers.
NYKD has a better Return On Equity (-18.90%) than 67.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.27% | ||
| ROE | -18.9% | ||
| ROIC | N/A |
ROA(3y)-20.49%
ROA(5y)0.02%
ROE(3y)-25.42%
ROE(5y)0.53%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NYKD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
NYKD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NYKD remains at a similar level compared to 1 year ago.
NYKD has more shares outstanding than it did 5 years ago.
The debt/assets ratio for NYKD has been reduced compared to a year ago.
2.2 Solvency
NYKD has an Altman-Z score of 3.75. This indicates that NYKD is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.75, NYKD belongs to the top of the industry, outperforming 81.08% of the companies in the same industry.
NYKD has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of NYKD (0.02) is better than 74.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.75 |
ROIC/WACCN/A
WACC8.53%
2.3 Liquidity
A Current Ratio of 16.92 indicates that NYKD has no problem at all paying its short term obligations.
With an excellent Current ratio value of 16.92, NYKD belongs to the best of the industry, outperforming 98.65% of the companies in the same industry.
A Quick Ratio of 16.92 indicates that NYKD has no problem at all paying its short term obligations.
NYKD has a better Quick ratio (16.92) than 98.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 16.92 | ||
| Quick Ratio | 16.92 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 90.47% over the past year.
Looking at the last year, NYKD shows a very negative growth in Revenue. The Revenue has decreased by -25.95% in the last year.
Measured over the past years, NYKD shows a very negative growth in Revenue. The Revenue has been decreasing by -36.54% on average per year.
EPS 1Y (TTM)90.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.2%
Revenue 1Y (TTM)-25.95%
Revenue growth 3Y-36.54%
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
NYKD is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -66.63% yearly.
Based on estimates for the next years, NYKD will show a very strong growth in Revenue. The Revenue will grow by 184.95% on average per year.
EPS Next Y82.99%
EPS Next 2Y18.52%
EPS Next 3Y14.21%
EPS Next 5Y-66.63%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y52.25%
Revenue Next 5Y184.95%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
NYKD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NYKD. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
NYKD's earnings are expected to grow with 14.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.52%
EPS Next 3Y14.21%
5. Dividend
5.1 Amount
NYKD has a Yearly Dividend Yield of 39.31%, which is a nice return.
NYKD's Dividend Yield is rather good when compared to the industry average which is at 11.17. NYKD pays more dividend than 100.00% of the companies in the same industry.
NYKD's Dividend Yield is rather good when compared to the S&P500 average which is at 2.36.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 39.31% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y18.52%
EPS Next 3Y14.21%
OSL:NYKD (11/12/2025, 7:00:00 PM)
2.238
-0.17 (-6.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners15.07%
Inst Owner ChangeN/A
Ins Owners0.96%
Ins Owner ChangeN/A
Market Cap730.82M
Revenue(TTM)7.85M
Net Income(TTM)-25.32M
Analysts42.22
Price Target5.25 (134.58%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 39.31% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.98%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)63.64%
EPS NY rev (3m)79.31%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 9.24 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.54 | ||
| P/tB | 0.54 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.12
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-1.47
OCFYN/A
SpS0.24
BVpS4.13
TBVpS4.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.27% | ||
| ROE | -18.9% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-20.49%
ROA(5y)0.02%
ROE(3y)-25.42%
ROE(5y)0.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 4.05% | ||
| Cap/Sales | 1.13% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 16.92 | ||
| Quick Ratio | 16.92 | ||
| Altman-Z | 3.75 |
F-Score4
WACC8.53%
ROIC/WACCN/A
Cap/Depr(3y)80.08%
Cap/Depr(5y)78.32%
Cap/Sales(3y)17.63%
Cap/Sales(5y)11.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.2%
EPS Next Y82.99%
EPS Next 2Y18.52%
EPS Next 3Y14.21%
EPS Next 5Y-66.63%
Revenue 1Y (TTM)-25.95%
Revenue growth 3Y-36.54%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y52.25%
Revenue Next 5Y184.95%
EBIT growth 1Y31.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.24%
EBIT Next 3Y17.05%
EBIT Next 5Y-60.17%
FCF growth 1Y10.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.72%
OCF growth 3YN/A
OCF growth 5YN/A
NYKODE THERAPEUTICS ASA / NYKD.OL FAQ
What is the ChartMill fundamental rating of NYKODE THERAPEUTICS ASA (NYKD.OL) stock?
ChartMill assigns a fundamental rating of 3 / 10 to NYKD.OL.
What is the valuation status for NYKD stock?
ChartMill assigns a valuation rating of 0 / 10 to NYKODE THERAPEUTICS ASA (NYKD.OL). This can be considered as Overvalued.
What is the profitability of NYKD stock?
NYKODE THERAPEUTICS ASA (NYKD.OL) has a profitability rating of 1 / 10.
What is the financial health of NYKODE THERAPEUTICS ASA (NYKD.OL) stock?
The financial health rating of NYKODE THERAPEUTICS ASA (NYKD.OL) is 6 / 10.